Background: HIV-1-specific CD8+ cytotoxic T lymphocytes (CTL) can play an important role in the long-term control of HIV-1 replication in vivo. Unfortunately, most HIV-1-infected persons are unable to control the virus with their T cell receptor (TCR) repertoire, due to inadequate coverage of epitope variation. A potential immunotherapeutic strategy for a functional cure could be the adoptive transfer of gene-modified T cells, equipped with a combination of TCRs covering all common variants of their targeted epitope. We developed a rapid methodology to identify epitope-specific TCR sequences and insert them into lentiviral vectors without need for HLA tetramers, cell sorting, or cell cloning.
Methods: We focused on five HIV-1 Gag epitopes based on common or protective HLA type and epitope conservation: KRWIILGLNK263-272 (KK10, HLA-B*2705), KAFSPEVIPMF162-172 (KF11, B*5701), GLNKIVRMY269-277 (GY9, B*1501), RQANFLGKI429-437 (RI9, B*1302), and WASRELERF36-44 (WF9, B*3501). Using a quantitative spectratyping method, we directly identified Gag-specific TCR sequences by expansion after epitope stimulation. Both TCR α and β chains were cloned in a one step reaction into a lentiviral vector. The functionality of these TCRs was examined through a Jurkat cell NFAT-dependent GFP reporter assay and also chromium release assays with transduced primary CD8+ T cells against HIV-1-infected T1 cells transduced with the relevant HLA genes. Panels of HIV-1 NL4-3 with common epitope variants were generated by point mutagenesis.
Results: We cloned and functionally confirmed sixteen TCRs (seven for KK10, four for KF11, three for GY9, one for RI9, and one for WF9). Several TCRs have been screened for their recognition of epitope variants and functional avidity using synthetic peptides, and will be screened for their antiviral activity against cells infected with HIV-1 containing these variants.
Conclusions: Our data demonstrate proof-of-concept for rapid TCR cloning into vectors suitable for gene therapy and capacity to screen these TCRs for ability to recognize epitope variants. This sets the foundation for combination TCR gene therapy to cover epitope variation.